Ann: Shareholder Update - Human & Canine Trials, page-30

Ok I put forward the above questions to Sam Wright and just received a reply.

In regards to when dosages will increase- this will take place as soon as 3 patients have completed the first trial for humans/canines (so 1 more canine and 2 more humans). Once completed the dosage will increase by 5 times the first dosage of PPL-1.

In regards to the reporting of the efficiency of PPL-1 it was explained as the following Generally, efficacy and pharmacokinetics will be determined by lab analysis
of urine, blood and tumour tissue as well as from tumour scans.
Assay results typically and in our case are done batch-wise on each
dose-group. In other words, when we finish a dosing level all the bloods and
tissues for those three patients are analysed. We will report on this as
soon as the work is done.

So we will receive the above information once each cohort is completed including the one currently underway. But it is unlikely to show any major information from the low dosage which is basically just to prove the drug is safe. The big results will come once the dosage is increased which will be happening soon.